Intensity Therapeutics of Wesport says that its lead drug INT230-6 6 results in complete response of tumors in rodent models, induces protective T-cell immunity and is synergistic with checkpoint inhibitors.

Intensity’s Chief Executive Officer Lewis H. Bender said, “The direct killing action and immune response data generated in rodent models from our lead drug INT230-6 are impressive. We hope these animal results translate into an equally potent response in our clinical study.”